Modern HPLC for practicing scientists / / by Michael Dong |
Autore | Dong M. W |
Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, 2006 |
Descrizione fisica | 1 online resource (306 p.) |
Disciplina |
543.0894
615.19 615/.19 |
Soggetto topico |
High performance liquid chromatography
Drugs - Analysis |
ISBN |
1-119-29360-X
1-280-45047-9 9786610450473 0-470-24575-1 0-471-97310-6 0-471-97309-2 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
MODERN HPLC FOR PRACTICING SCIENTISTS; CONTENTS; Preface; 1 Introduction; 1.1 Introduction; 1.1.1 Scope; 1.1.2 What Is HPLC?; 1.1.3 A Brief History; 1.1.4 Advantages and Limitations; 1.2 Modes of HPLC; 1.2.1 Normal-Phase Chromatography (NPC); 1.2.2 Reversed-Phase Chromatography (RPC); 1.2.3 Ion-Exchange Chromatography (IEC); 1.2.4 Size-Exclusion Chromatography (SEC); 1.2.5 Other Separation Modes; 1.3 Some Common-Sense Corollaries; 1.4 How to Get More Information; 1.5 Summary; 1.6 References; 2 Basic Terms and Concepts; 2.1 Scope; 2.2 Basic Terms and Concepts
2.2.1 Retention Time (t(R)), Void Time (t(M)), Peak Height (h), and Peak Width (w(b))2.2.2 Retention Volume (V(R)), Void Volume (V(M)), and Peak Volume; 2.2.3 Retention Factor (k); 2.2.4 Separation Factor (a); 2.2.5 Column Efficiency and Plate Number (N); 2.2.6 Peak Volume; 2.2.7 Height Equivalent to a Theoretical Plate or Plate Height (HETP or H); 2.2.8 Resolution (R(s)); 2.2.9 Peak Symmetry: Asymmetry Factor (A(s)) and Tailing Factor (T(f)); 2.3 Mobile Phase; 2.3.1 General Requirements; 2.3.2 Solvent Strength and Selectivity; 2.3.3 Buffers; 2.3.4 Acidic Mobile Phases 2.3.5 Ion-Pairing Additives2.3.6 High pH Mobile Phase; 2.3.7 Other Operating Parameters: Flow Rate (F) and Column Temperature (T); 2.4 The Resolution Equation; 2.5 The Van Deemter Equation; 2.6 Isocratic vs. Gradient Analysis; 2.6.1 Peak Capacity (n); 2.6.2 Key Gradient Parameters (Initial and Final Solvent Strength, Gradient Time [t(G)], and Flow Rate); 2.6.3 The 0.25Dt(G) Rule:When Is Isocratic Analysis More Appropriate?; 2.7 Concept of Orthogonality; 2.8 Sample Capacity; 2.9 Glossary of HPLC Terms; 2.10 Summary and Conclusion; 2.11 References; 3 HPLC Columns and Trends; 3.1 Scope 3.2 General Column Description and Characteristics 3.2.1 Column Hardware-Standard vs. Cartridge Format; 3.3 Column Types; 3.3.1 Types Based on Chromatographic Modes; 3.3.2 Types Based on Dimensions; 3.3.3 Column Length (L); 3.4 Column Packing Characteristics; 3.4.1 Support Type; 3.4.2 Particle Size (d(p)); 3.4.3 Surface Area and Pore Size (d(pore)); 3.4.4 Bonding Chemistries; 3.4.5 Some General Guidelines for Bonded Phase Selection; 3.5 Modern HPLC Column Trends; 3.5.1 High-Purity Silica; 3.5.2 Hybrid Particles; 3.5.3 Novel Bonding Chemistries; 3.5.4 Fast LC; 3.5.5 Micro LC; 3.5.6 Monoliths 3.6 Guard Columns3.7 Specialty Columns; 3.7.1 Bioseparation Columns; 3.7.2 Chiral Columns; 3.7.3 Application-Specific Columns; 3.8 Column Selection Guides; 3.9 Summary; 3.10 References; 3.11 Internet Resources; 4 HPLC Instrumentation and Trends; 4.1 Introduction; 4.1.1 Scope; 4.1.2 HPLC Systems and Modules; 4.2 HPLC Solvent Delivery Systems; 4.2.1 High-Pressure and Low-Pressure Mixing Designs in Multisolvent Pumps; 4.2.2 System Dwell Volume; 4.2.3 Trends; 4.3 Injectors and Autosamplers; 4.3.1 Operating Principles of Autosamplers; 4.3.2 Performance Characteristics and Trends; 4.4 Detectors 4.5 UV/VIS Absorbance Detectors |
Record Nr. | UNINA-9910143397603321 |
Dong M. W
![]() |
||
Hoboken, N.J., : Wiley-Interscience, 2006 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Modern HPLC for practicing scientists / / by Michael Dong |
Autore | Dong M. W |
Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, 2006 |
Descrizione fisica | 1 online resource (306 p.) |
Disciplina |
543.0894
615.19 615/.19 |
Soggetto topico |
High performance liquid chromatography
Drugs - Analysis |
ISBN |
1-119-29360-X
1-280-45047-9 9786610450473 0-470-24575-1 0-471-97310-6 0-471-97309-2 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
MODERN HPLC FOR PRACTICING SCIENTISTS; CONTENTS; Preface; 1 Introduction; 1.1 Introduction; 1.1.1 Scope; 1.1.2 What Is HPLC?; 1.1.3 A Brief History; 1.1.4 Advantages and Limitations; 1.2 Modes of HPLC; 1.2.1 Normal-Phase Chromatography (NPC); 1.2.2 Reversed-Phase Chromatography (RPC); 1.2.3 Ion-Exchange Chromatography (IEC); 1.2.4 Size-Exclusion Chromatography (SEC); 1.2.5 Other Separation Modes; 1.3 Some Common-Sense Corollaries; 1.4 How to Get More Information; 1.5 Summary; 1.6 References; 2 Basic Terms and Concepts; 2.1 Scope; 2.2 Basic Terms and Concepts
2.2.1 Retention Time (t(R)), Void Time (t(M)), Peak Height (h), and Peak Width (w(b))2.2.2 Retention Volume (V(R)), Void Volume (V(M)), and Peak Volume; 2.2.3 Retention Factor (k); 2.2.4 Separation Factor (a); 2.2.5 Column Efficiency and Plate Number (N); 2.2.6 Peak Volume; 2.2.7 Height Equivalent to a Theoretical Plate or Plate Height (HETP or H); 2.2.8 Resolution (R(s)); 2.2.9 Peak Symmetry: Asymmetry Factor (A(s)) and Tailing Factor (T(f)); 2.3 Mobile Phase; 2.3.1 General Requirements; 2.3.2 Solvent Strength and Selectivity; 2.3.3 Buffers; 2.3.4 Acidic Mobile Phases 2.3.5 Ion-Pairing Additives2.3.6 High pH Mobile Phase; 2.3.7 Other Operating Parameters: Flow Rate (F) and Column Temperature (T); 2.4 The Resolution Equation; 2.5 The Van Deemter Equation; 2.6 Isocratic vs. Gradient Analysis; 2.6.1 Peak Capacity (n); 2.6.2 Key Gradient Parameters (Initial and Final Solvent Strength, Gradient Time [t(G)], and Flow Rate); 2.6.3 The 0.25Dt(G) Rule:When Is Isocratic Analysis More Appropriate?; 2.7 Concept of Orthogonality; 2.8 Sample Capacity; 2.9 Glossary of HPLC Terms; 2.10 Summary and Conclusion; 2.11 References; 3 HPLC Columns and Trends; 3.1 Scope 3.2 General Column Description and Characteristics 3.2.1 Column Hardware-Standard vs. Cartridge Format; 3.3 Column Types; 3.3.1 Types Based on Chromatographic Modes; 3.3.2 Types Based on Dimensions; 3.3.3 Column Length (L); 3.4 Column Packing Characteristics; 3.4.1 Support Type; 3.4.2 Particle Size (d(p)); 3.4.3 Surface Area and Pore Size (d(pore)); 3.4.4 Bonding Chemistries; 3.4.5 Some General Guidelines for Bonded Phase Selection; 3.5 Modern HPLC Column Trends; 3.5.1 High-Purity Silica; 3.5.2 Hybrid Particles; 3.5.3 Novel Bonding Chemistries; 3.5.4 Fast LC; 3.5.5 Micro LC; 3.5.6 Monoliths 3.6 Guard Columns3.7 Specialty Columns; 3.7.1 Bioseparation Columns; 3.7.2 Chiral Columns; 3.7.3 Application-Specific Columns; 3.8 Column Selection Guides; 3.9 Summary; 3.10 References; 3.11 Internet Resources; 4 HPLC Instrumentation and Trends; 4.1 Introduction; 4.1.1 Scope; 4.1.2 HPLC Systems and Modules; 4.2 HPLC Solvent Delivery Systems; 4.2.1 High-Pressure and Low-Pressure Mixing Designs in Multisolvent Pumps; 4.2.2 System Dwell Volume; 4.2.3 Trends; 4.3 Injectors and Autosamplers; 4.3.1 Operating Principles of Autosamplers; 4.3.2 Performance Characteristics and Trends; 4.4 Detectors 4.5 UV/VIS Absorbance Detectors |
Record Nr. | UNINA-9910830997203321 |
Dong M. W
![]() |
||
Hoboken, N.J., : Wiley-Interscience, 2006 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Modern HPLC for practicing scientists / / by Michael Dong |
Autore | Dong M. W |
Pubbl/distr/stampa | Hoboken, N.J., : Wiley-Interscience, 2006 |
Descrizione fisica | 1 online resource (306 p.) |
Disciplina |
543.0894
615.19 615/.19 |
Soggetto topico |
High performance liquid chromatography
Drugs - Analysis |
ISBN |
1-119-29360-X
1-280-45047-9 9786610450473 0-470-24575-1 0-471-97310-6 0-471-97309-2 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
MODERN HPLC FOR PRACTICING SCIENTISTS; CONTENTS; Preface; 1 Introduction; 1.1 Introduction; 1.1.1 Scope; 1.1.2 What Is HPLC?; 1.1.3 A Brief History; 1.1.4 Advantages and Limitations; 1.2 Modes of HPLC; 1.2.1 Normal-Phase Chromatography (NPC); 1.2.2 Reversed-Phase Chromatography (RPC); 1.2.3 Ion-Exchange Chromatography (IEC); 1.2.4 Size-Exclusion Chromatography (SEC); 1.2.5 Other Separation Modes; 1.3 Some Common-Sense Corollaries; 1.4 How to Get More Information; 1.5 Summary; 1.6 References; 2 Basic Terms and Concepts; 2.1 Scope; 2.2 Basic Terms and Concepts
2.2.1 Retention Time (t(R)), Void Time (t(M)), Peak Height (h), and Peak Width (w(b))2.2.2 Retention Volume (V(R)), Void Volume (V(M)), and Peak Volume; 2.2.3 Retention Factor (k); 2.2.4 Separation Factor (a); 2.2.5 Column Efficiency and Plate Number (N); 2.2.6 Peak Volume; 2.2.7 Height Equivalent to a Theoretical Plate or Plate Height (HETP or H); 2.2.8 Resolution (R(s)); 2.2.9 Peak Symmetry: Asymmetry Factor (A(s)) and Tailing Factor (T(f)); 2.3 Mobile Phase; 2.3.1 General Requirements; 2.3.2 Solvent Strength and Selectivity; 2.3.3 Buffers; 2.3.4 Acidic Mobile Phases 2.3.5 Ion-Pairing Additives2.3.6 High pH Mobile Phase; 2.3.7 Other Operating Parameters: Flow Rate (F) and Column Temperature (T); 2.4 The Resolution Equation; 2.5 The Van Deemter Equation; 2.6 Isocratic vs. Gradient Analysis; 2.6.1 Peak Capacity (n); 2.6.2 Key Gradient Parameters (Initial and Final Solvent Strength, Gradient Time [t(G)], and Flow Rate); 2.6.3 The 0.25Dt(G) Rule:When Is Isocratic Analysis More Appropriate?; 2.7 Concept of Orthogonality; 2.8 Sample Capacity; 2.9 Glossary of HPLC Terms; 2.10 Summary and Conclusion; 2.11 References; 3 HPLC Columns and Trends; 3.1 Scope 3.2 General Column Description and Characteristics 3.2.1 Column Hardware-Standard vs. Cartridge Format; 3.3 Column Types; 3.3.1 Types Based on Chromatographic Modes; 3.3.2 Types Based on Dimensions; 3.3.3 Column Length (L); 3.4 Column Packing Characteristics; 3.4.1 Support Type; 3.4.2 Particle Size (d(p)); 3.4.3 Surface Area and Pore Size (d(pore)); 3.4.4 Bonding Chemistries; 3.4.5 Some General Guidelines for Bonded Phase Selection; 3.5 Modern HPLC Column Trends; 3.5.1 High-Purity Silica; 3.5.2 Hybrid Particles; 3.5.3 Novel Bonding Chemistries; 3.5.4 Fast LC; 3.5.5 Micro LC; 3.5.6 Monoliths 3.6 Guard Columns3.7 Specialty Columns; 3.7.1 Bioseparation Columns; 3.7.2 Chiral Columns; 3.7.3 Application-Specific Columns; 3.8 Column Selection Guides; 3.9 Summary; 3.10 References; 3.11 Internet Resources; 4 HPLC Instrumentation and Trends; 4.1 Introduction; 4.1.1 Scope; 4.1.2 HPLC Systems and Modules; 4.2 HPLC Solvent Delivery Systems; 4.2.1 High-Pressure and Low-Pressure Mixing Designs in Multisolvent Pumps; 4.2.2 System Dwell Volume; 4.2.3 Trends; 4.3 Injectors and Autosamplers; 4.3.1 Operating Principles of Autosamplers; 4.3.2 Performance Characteristics and Trends; 4.4 Detectors 4.5 UV/VIS Absorbance Detectors |
Record Nr. | UNINA-9910877540503321 |
Dong M. W
![]() |
||
Hoboken, N.J., : Wiley-Interscience, 2006 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Modified-release drug delivery technology / / edited by Michael J. Rathbone [et al.] |
Edizione | [Second edition.] |
Pubbl/distr/stampa | New York : , : CRC Press, , 2008 |
Descrizione fisica | 1 online resource (2 volumes) : illustrations |
Disciplina | 615/.19 |
Altri autori (Persone) |
RathboneMichael J. <1957->
HadgraftJonathan <1950-> RobertsMichael S. <1949-> LaneMajella E |
Collana | Drugs and the pharmaceutical sciences |
Soggetto topico |
Controlled release technology
Controlled release preparations Drug delivery systems Pharmaceutical technology |
ISBN |
0-429-09286-5
1-4200-4526-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Preface""; ""Contents""; ""Contributors""; ""1 The Modified-Release Drug Delivery Landscape""; ""2 The Modified-Release Drug Delivery Landscape""; ""3 The Modified-Release Drug Delivery Landscape""; ""4 The Modified-Release Drug Delivery Landscape""; ""5 Ophthalmic Drug Delivery""; ""6 Intraocular Implants for Controlled Drug Delivery""; ""7 Bioadhesive Ophthalmic Drug Inserts (BODI) for Veterinary Use""; ""8 Ion Exchange Resin Technology for Ophthalmic Applications""; ""9 Injections and Implants""; ""10 Long-Acting Protein Formulation-PLAD Technology""
""11 Long-Term Controlled Delivery of Therapeutic Agents by the Osmotically Driven DUROS Implant""; ""12 The SABERTM Delivery System for Parenteral Administration""; ""13 Improving the Delivery of Complex Formulations Using the DepotOne Needle""; ""14 ReGel Depot Technology""; ""15 The Atrigel Drug Delivery System""; ""16 Enhancing Drug Delivery by Chemical Modification""; ""17 DepoFoam Multivesicular Liposomes for the Sustained Release of Macromolecules""; ""18 ALZAMER DepotTM Bioerodible Polymer Technology"" ""19 Pegylated Liposome Delivery of Chemotherapeutic Agents: Rationale and Clinical Benefit""; ""20 Dermal and Transdermal Drug Delivery""; ""21 ALZA Transdermal Drug Delivery Technologies""; ""22 Microneedles for Drug Delivery""; ""23 Transfersome: Self-Optimizing and Self-Driven Drug-Carrier, for Localized and Transdermal Drug Delivery""; ""24 Advances in Wound Healing""; ""25 Ultrasound-Mediated Transdermal Drug Delivery""; ""26 Lipid Nanoparticles with Solid Matrix for Dermal Delivery: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers"" ""27 LidoSite-Vyteris Iontophoretic Technology""; ""28 Nail Delivery""; ""29 Immediate Topical Drug Delivery Using Natural Nano-Injectors""; ""30 DOT Matrix Technology""; ""31 The PassPortTM System: A New Transdermal Patch for Water-Soluble Drugs, Proteins, and Carbohydrates""; ""32 Nasal Drug Delivery""; ""33 Controlled Particle Dispersion: A Twenty-First-Century Nasal Drug Delivery Platform""; ""34 DirectHalerTM Nasal: Innovative Device and Delivery Method""; ""35 Intravaginal Drug Delivery Technologies""; ""36 Vaginal Rings for Controlled-Release Drug Delivery"" ""37 Phospholipids as Carriers for Vaginal Drug Delivery""; ""38 SITE RELEASE, Vaginal Bioadhesive System""; ""39 Clindamycin Vaginal Insert""; ""40 Bioresponsive Vaginal Delivery Systems""; ""41 Pulmonary Delivery of Drugs by Inhalation""; ""42 AERx Pulmonary Drug Delivery Systems""; ""43 Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols""; ""44 Adaptive Aerosol Delivery (AAD) Technology""; ""45 Nebulizer Technologies""; ""46 Formulation Challenges: Protein Powders for Inhalation"" ; ""47 The Respimat, a New Soft MistTM Inhaler for Delivering Drugs to the Lungs"" |
Record Nr. | UNINA-9910780901203321 |
New York : , : CRC Press, , 2008 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Modified-release drug delivery technology / / edited by Michael J. Rathbone [et al.] |
Edizione | [Second edition.] |
Pubbl/distr/stampa | New York : , : CRC Press, , 2008 |
Descrizione fisica | 1 online resource (2 volumes) : illustrations |
Disciplina | 615/.19 |
Altri autori (Persone) |
RathboneMichael J. <1957->
HadgraftJonathan <1950-> RobertsMichael S. <1949-> LaneMajella E |
Collana | Drugs and the pharmaceutical sciences |
Soggetto topico |
Controlled release technology
Controlled release preparations Drug delivery systems Pharmaceutical technology |
ISBN |
0-429-09286-5
1-4200-4526-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Preface""; ""Contents""; ""Contributors""; ""1 The Modified-Release Drug Delivery Landscape""; ""2 The Modified-Release Drug Delivery Landscape""; ""3 The Modified-Release Drug Delivery Landscape""; ""4 The Modified-Release Drug Delivery Landscape""; ""5 Ophthalmic Drug Delivery""; ""6 Intraocular Implants for Controlled Drug Delivery""; ""7 Bioadhesive Ophthalmic Drug Inserts (BODI) for Veterinary Use""; ""8 Ion Exchange Resin Technology for Ophthalmic Applications""; ""9 Injections and Implants""; ""10 Long-Acting Protein Formulation-PLAD Technology""
""11 Long-Term Controlled Delivery of Therapeutic Agents by the Osmotically Driven DUROS Implant""; ""12 The SABERTM Delivery System for Parenteral Administration""; ""13 Improving the Delivery of Complex Formulations Using the DepotOne Needle""; ""14 ReGel Depot Technology""; ""15 The Atrigel Drug Delivery System""; ""16 Enhancing Drug Delivery by Chemical Modification""; ""17 DepoFoam Multivesicular Liposomes for the Sustained Release of Macromolecules""; ""18 ALZAMER DepotTM Bioerodible Polymer Technology"" ""19 Pegylated Liposome Delivery of Chemotherapeutic Agents: Rationale and Clinical Benefit""; ""20 Dermal and Transdermal Drug Delivery""; ""21 ALZA Transdermal Drug Delivery Technologies""; ""22 Microneedles for Drug Delivery""; ""23 Transfersome: Self-Optimizing and Self-Driven Drug-Carrier, for Localized and Transdermal Drug Delivery""; ""24 Advances in Wound Healing""; ""25 Ultrasound-Mediated Transdermal Drug Delivery""; ""26 Lipid Nanoparticles with Solid Matrix for Dermal Delivery: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers"" ""27 LidoSite-Vyteris Iontophoretic Technology""; ""28 Nail Delivery""; ""29 Immediate Topical Drug Delivery Using Natural Nano-Injectors""; ""30 DOT Matrix Technology""; ""31 The PassPortTM System: A New Transdermal Patch for Water-Soluble Drugs, Proteins, and Carbohydrates""; ""32 Nasal Drug Delivery""; ""33 Controlled Particle Dispersion: A Twenty-First-Century Nasal Drug Delivery Platform""; ""34 DirectHalerTM Nasal: Innovative Device and Delivery Method""; ""35 Intravaginal Drug Delivery Technologies""; ""36 Vaginal Rings for Controlled-Release Drug Delivery"" ""37 Phospholipids as Carriers for Vaginal Drug Delivery""; ""38 SITE RELEASE, Vaginal Bioadhesive System""; ""39 Clindamycin Vaginal Insert""; ""40 Bioresponsive Vaginal Delivery Systems""; ""41 Pulmonary Delivery of Drugs by Inhalation""; ""42 AERx Pulmonary Drug Delivery Systems""; ""43 Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols""; ""44 Adaptive Aerosol Delivery (AAD) Technology""; ""45 Nebulizer Technologies""; ""46 Formulation Challenges: Protein Powders for Inhalation"" ; ""47 The Respimat, a New Soft MistTM Inhaler for Delivering Drugs to the Lungs"" |
Record Nr. | UNINA-9910800075903321 |
New York : , : CRC Press, , 2008 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Modified-release drug delivery technology . Volume 2 / / edited by Michael J. Rathbone ... [et al.] |
Edizione | [2nd ed.] |
Pubbl/distr/stampa | New York, : Informa Healthcare, c2008 |
Descrizione fisica | 1 online resource (2 volumes) : illustrations |
Disciplina | 615/.19 |
Altri autori (Persone) | RathboneMichael J. <1957-> |
Collana | Drugs and the pharmaceutical sciences |
Soggetto topico |
Controlled release technology
Controlled release preparations Drug delivery systems Pharmaceutical technology |
ISBN |
0-429-09286-5
1-4200-4526-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Preface""; ""Contents""; ""Contributors""; ""1 The Modified-Release Drug Delivery Landscape""; ""2 The Modified-Release Drug Delivery Landscape""; ""3 The Modified-Release Drug Delivery Landscape""; ""4 The Modified-Release Drug Delivery Landscape""; ""5 Ophthalmic Drug Delivery""; ""6 Intraocular Implants for Controlled Drug Delivery""; ""7 Bioadhesive Ophthalmic Drug Inserts (BODI) for Veterinary Use""; ""8 Ion Exchange Resin Technology for Ophthalmic Applications""; ""9 Injections and Implants""; ""10 Long-Acting Protein Formulation-PLAD Technology""
""11 Long-Term Controlled Delivery of Therapeutic Agents by the Osmotically Driven DUROS Implant""; ""12 The SABERTM Delivery System for Parenteral Administration""; ""13 Improving the Delivery of Complex Formulations Using the DepotOne Needle""; ""14 ReGel Depot Technology""; ""15 The Atrigel Drug Delivery System""; ""16 Enhancing Drug Delivery by Chemical Modification""; ""17 DepoFoam Multivesicular Liposomes for the Sustained Release of Macromolecules""; ""18 ALZAMER DepotTM Bioerodible Polymer Technology"" ""19 Pegylated Liposome Delivery of Chemotherapeutic Agents: Rationale and Clinical Benefit""; ""20 Dermal and Transdermal Drug Delivery""; ""21 ALZA Transdermal Drug Delivery Technologies""; ""22 Microneedles for Drug Delivery""; ""23 Transfersome: Self-Optimizing and Self-Driven Drug-Carrier, for Localized and Transdermal Drug Delivery""; ""24 Advances in Wound Healing""; ""25 Ultrasound-Mediated Transdermal Drug Delivery""; ""26 Lipid Nanoparticles with Solid Matrix for Dermal Delivery: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers"" ""27 LidoSite-Vyteris Iontophoretic Technology""; ""28 Nail Delivery""; ""29 Immediate Topical Drug Delivery Using Natural Nano-Injectors""; ""30 DOT Matrix Technology""; ""31 The PassPortTM System: A New Transdermal Patch for Water-Soluble Drugs, Proteins, and Carbohydrates""; ""32 Nasal Drug Delivery""; ""33 Controlled Particle Dispersion: A Twenty-First-Century Nasal Drug Delivery Platform""; ""34 DirectHalerTM Nasal: Innovative Device and Delivery Method""; ""35 Intravaginal Drug Delivery Technologies""; ""36 Vaginal Rings for Controlled-Release Drug Delivery"" ""37 Phospholipids as Carriers for Vaginal Drug Delivery""; ""38 SITE RELEASE, Vaginal Bioadhesive System""; ""39 Clindamycin Vaginal Insert""; ""40 Bioresponsive Vaginal Delivery Systems""; ""41 Pulmonary Delivery of Drugs by Inhalation""; ""42 AERx Pulmonary Drug Delivery Systems""; ""43 Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols""; ""44 Adaptive Aerosol Delivery (AAD) Technology""; ""45 Nebulizer Technologies""; ""46 Formulation Challenges: Protein Powders for Inhalation"" ; ""47 The Respimat, a New Soft MistTM Inhaler for Delivering Drugs to the Lungs"" |
Record Nr. | UNINA-9910807468003321 |
New York, : Informa Healthcare, c2008 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Modified-Release Drug Delivery Technology, Second Edition : Modified Release Drug Delivery Technology, Volume 2 |
Autore | Rathbone Michael J |
Edizione | [2nd ed.] |
Pubbl/distr/stampa | New York : , : CRC Press, , 2008 |
Descrizione fisica | 1 online resource (727 p.) |
Disciplina | 615/.19 |
Altri autori (Persone) |
HadgraftJonathan
RobertsMichael S LaneMajella E |
Collana | Drugs and the pharmaceutical sciences |
Soggetto topico |
Controlled release technology
Controlled release preparations Drug delivery systems Pharmaceutical technology |
Soggetto genere / forma | Electronic books. |
ISBN |
0-429-09286-5
1-4200-4526-1 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
""Preface""; ""Contents""; ""Contributors""; ""1 The Modified-Release Drug Delivery Landscape""; ""2 The Modified-Release Drug Delivery Landscape""; ""3 The Modified-Release Drug Delivery Landscape""; ""4 The Modified-Release Drug Delivery Landscape""; ""5 Ophthalmic Drug Delivery""; ""6 Intraocular Implants for Controlled Drug Delivery""; ""7 Bioadhesive Ophthalmic Drug Inserts (BODI) for Veterinary Use""; ""8 Ion Exchange Resin Technology for Ophthalmic Applications""; ""9 Injections and Implants""; ""10 Long-Acting Protein Formulation�PLAD Technology""
""11 Long-Term Controlled Delivery of Therapeutic Agents by the Osmotically Driven DUROS Implant""""12 The SABERTM Delivery System for Parenteral Administration""; ""13 Improving the Delivery of Complex Formulations Using the DepotOne Needle""; ""14 ReGel Depot Technology""; ""15 The Atrigel Drug Delivery System""; ""16 Enhancing Drug Delivery by Chemical Modification""; ""17 DepoFoam Multivesicular Liposomes for the Sustained Release of Macromolecules""; ""18 ALZAMER DepotTM Bioerodible Polymer Technology"" ""19 Pegylated Liposome Delivery of Chemotherapeutic Agents: Rationale and Clinical Benefit""""20 Dermal and Transdermal Drug Delivery""; ""21 ALZA Transdermal Drug Delivery Technologies""; ""22 Microneedles for Drug Delivery""; ""23 Transfersome: Self-Optimizing and Self-Driven Drug-Carrier, for Localized and Transdermal Drug Delivery""; ""24 Advances in Wound Healing""; ""25 Ultrasound-Mediated Transdermal Drug Delivery""; ""26 Lipid Nanoparticles with Solid Matrix for Dermal Delivery: Solid Lipid Nanoparticles and Nanostructured Lipid Carriers"" ""27 LidoSite�Vyteris Iontophoretic Technology""""28 Nail Delivery""; ""29 Immediate Topical Drug Delivery Using Natural Nano-Injectors""; ""30 DOT Matrix Technology""; ""31 The PassPortTM System: A New Transdermal Patch for Water-Soluble Drugs, Proteins, and Carbohydrates""; ""32 Nasal Drug Delivery""; ""33 Controlled Particle Dispersion: A Twenty-First-Century Nasal Drug Delivery Platform""; ""34 DirectHalerTM Nasal: Innovative Device and Delivery Method""; ""35 Intravaginal Drug Delivery Technologies""; ""36 Vaginal Rings for Controlled-Release Drug Delivery"" ""37 Phospholipids as Carriers for Vaginal Drug Delivery""""38 SITE RELEASE, Vaginal Bioadhesive System""; ""39 Clindamycin Vaginal Insert""; ""40 Bioresponsive Vaginal Delivery Systems""; ""41 Pulmonary Delivery of Drugs by Inhalation""; ""42 AERx Pulmonary Drug Delivery Systems""; ""43 Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols""; ""44 Adaptive Aerosol Delivery (AAD) Technology""; ""45 Nebulizer Technologies""; ""46 Formulation Challenges: Protein Powders for Inhalation"" ""47 The Respimat, a New Soft MistTM Inhaler for Delivering Drugs to the Lungs"" |
Record Nr. | UNINA-9910455928003321 |
Rathbone Michael J
![]() |
||
New York : , : CRC Press, , 2008 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Molecular pathology in drug discovery and development [[electronic resource] /] / edited by J. Suso Platero |
Pubbl/distr/stampa | Hoboken, N.J., : John Wiley, c2009 |
Descrizione fisica | 1 online resource (396 p.) |
Disciplina | 615/.19 |
Altri autori (Persone) | PlateroJ. Suso |
Soggetto topico |
Drug development
Pathology, Molecular |
ISBN |
1-282-27956-4
9786612279560 0-470-47595-1 0-470-47594-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
MOLECULAR PATHOLOGY IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; Preface; Contributors; 1 MOLECULAR PATHOLOGY AND DRUG DEVELOPMENT; 1.1. General Pathology; 1.2. General Aspects; 1.3. Molecular Pathology, the Molecular Way; 1.3.1. Loss of Gene Expression; 1.3.2. Translocations; 1.3.3. Detection of Pathogens; 1.3.4. Forensic Identification; 1.3.5. Protein Changes; 1.3.6. Other Methods of Detection; 1.4. Application of Molecular Pathology; 1.5. Molecular Pathology in Drug Development; 1.5.1. Most Important Molecular Pathologic Consideration; 1.6. Pharmaceutical Drug Development
1.6.1. Introduction1.6.2. Drug Discovery and Development; References; 2 MOLECULAR PATHOLOGY IN ONCOLOGY TARGET AND DRUG DISCOVERY; 2.1. Introduction; 2.2. History of Chemotherapy and Cancer Drug Discovery; 2.3. Target-Based Drug Discovery; 2.4. Utilization of Molecular Pathology in the Discovery of Novel Cancer Targets; 2.5. Hit Identification and In Vitro Lead Optimization; 2.6. Implications for Molecular Pathology in Cancer Drug Development and Use; 2.7. Summary and Future Considerations; References; 3 MOLECULAR PATHOLOGY AND TRANSCRIPTIONAL PROFILING IN EARLY DRUG DEVELOPMENT 3.1. Introduction3.2. Biomarkers in Clinical Setting and in Early Drug Development; 3.3. Advantages of Biomarker Implementation; 3.4. Changing Paradigm in Clinical Drug and Biomarker Development; 3.5. Promises of Transcriptional Profiling; 3.6. Biomarker Development and Validation Using Microarray Analysis; 3.7. Neoadjuvant Chemotherapy as an Intriguing Model for Biomarker Development; 3.8. Transcriptional Profiling for Identification of Individual Genes as Biomarkers; 3.9. Transcriptional Profiling for the Definition of Multigene Predictors Using Transcriptional Profiling 3.9.1. Multigene Predictors of Chemotherapy Response3.9.2. Multigene Predictor of Response to a Targeted Therapy Agent; 3.9.3. Novel Approaches to Phase II Clinical Trial Design; 3.10. Novel Tools for Pathway Analysis; 3.11. Implementation of Biomarkers into the Clinical Setting; 3.12. Conclusion; References; 4 MOLECULAR PATHOLOGY IN NONCLINICAL SAFETY ASSESSMENT; 4.1. Introduction; 4.2. Drug Development; 4.2.1. Immunohistochemistry in Drug Development; 4.3. Drug Discovery; 4.3.1. Target Validation and Target-Related Safety Concerns; 4.3.2. Off-Target Effects; 4.4. Biopharmaceuticals 4.5. SummaryReferences; 5 TOXICOGENOMICS IN DRUG DEVELOPMENT; 5.1. Introduction; 5.2. Brief Overview of Large-Scale Gene Expression Technologies; 5.2.1. RNA Quality; 5.2.2. Hybridization Platforms; 5.3. Analysis of Microarray Data; 5.3.1. Normalization and Filtering; 5.3.2. Analyzing for Differences between Experimental Samples; 5.3.3. Familywise Error Rate; 5.3.4. Resampling; 5.3.5. Expression Profile Analysis; 5.3.6. Pathway Analysis; 5.3.7. Gene Expression Databases; 5.3.8. Analyzing Relatedness of Gene Expression Profiles; 5.4. Application of Toxicogenomics in Drug Development 5.4.1. Discovery |
Record Nr. | UNINA-9910139922403321 |
Hoboken, N.J., : John Wiley, c2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Molecular pathology in drug discovery and development / / edited by J. Suso Platero |
Edizione | [1st ed.] |
Pubbl/distr/stampa | Hoboken, N.J., : John Wiley, c2009 |
Descrizione fisica | 1 online resource (396 p.) |
Disciplina | 615/.19 |
Altri autori (Persone) | PlateroJ. Suso |
Soggetto topico |
Drug development
Pathology, Molecular |
ISBN |
1-282-27956-4
9786612279560 0-470-47595-1 0-470-47594-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
MOLECULAR PATHOLOGY IN DRUG DISCOVERY AND DEVELOPMENT; CONTENTS; Preface; Contributors; 1 MOLECULAR PATHOLOGY AND DRUG DEVELOPMENT; 1.1. General Pathology; 1.2. General Aspects; 1.3. Molecular Pathology, the Molecular Way; 1.3.1. Loss of Gene Expression; 1.3.2. Translocations; 1.3.3. Detection of Pathogens; 1.3.4. Forensic Identification; 1.3.5. Protein Changes; 1.3.6. Other Methods of Detection; 1.4. Application of Molecular Pathology; 1.5. Molecular Pathology in Drug Development; 1.5.1. Most Important Molecular Pathologic Consideration; 1.6. Pharmaceutical Drug Development
1.6.1. Introduction1.6.2. Drug Discovery and Development; References; 2 MOLECULAR PATHOLOGY IN ONCOLOGY TARGET AND DRUG DISCOVERY; 2.1. Introduction; 2.2. History of Chemotherapy and Cancer Drug Discovery; 2.3. Target-Based Drug Discovery; 2.4. Utilization of Molecular Pathology in the Discovery of Novel Cancer Targets; 2.5. Hit Identification and In Vitro Lead Optimization; 2.6. Implications for Molecular Pathology in Cancer Drug Development and Use; 2.7. Summary and Future Considerations; References; 3 MOLECULAR PATHOLOGY AND TRANSCRIPTIONAL PROFILING IN EARLY DRUG DEVELOPMENT 3.1. Introduction3.2. Biomarkers in Clinical Setting and in Early Drug Development; 3.3. Advantages of Biomarker Implementation; 3.4. Changing Paradigm in Clinical Drug and Biomarker Development; 3.5. Promises of Transcriptional Profiling; 3.6. Biomarker Development and Validation Using Microarray Analysis; 3.7. Neoadjuvant Chemotherapy as an Intriguing Model for Biomarker Development; 3.8. Transcriptional Profiling for Identification of Individual Genes as Biomarkers; 3.9. Transcriptional Profiling for the Definition of Multigene Predictors Using Transcriptional Profiling 3.9.1. Multigene Predictors of Chemotherapy Response3.9.2. Multigene Predictor of Response to a Targeted Therapy Agent; 3.9.3. Novel Approaches to Phase II Clinical Trial Design; 3.10. Novel Tools for Pathway Analysis; 3.11. Implementation of Biomarkers into the Clinical Setting; 3.12. Conclusion; References; 4 MOLECULAR PATHOLOGY IN NONCLINICAL SAFETY ASSESSMENT; 4.1. Introduction; 4.2. Drug Development; 4.2.1. Immunohistochemistry in Drug Development; 4.3. Drug Discovery; 4.3.1. Target Validation and Target-Related Safety Concerns; 4.3.2. Off-Target Effects; 4.4. Biopharmaceuticals 4.5. SummaryReferences; 5 TOXICOGENOMICS IN DRUG DEVELOPMENT; 5.1. Introduction; 5.2. Brief Overview of Large-Scale Gene Expression Technologies; 5.2.1. RNA Quality; 5.2.2. Hybridization Platforms; 5.3. Analysis of Microarray Data; 5.3.1. Normalization and Filtering; 5.3.2. Analyzing for Differences between Experimental Samples; 5.3.3. Familywise Error Rate; 5.3.4. Resampling; 5.3.5. Expression Profile Analysis; 5.3.6. Pathway Analysis; 5.3.7. Gene Expression Databases; 5.3.8. Analyzing Relatedness of Gene Expression Profiles; 5.4. Application of Toxicogenomics in Drug Development 5.4.1. Discovery |
Record Nr. | UNINA-9910812380703321 |
Hoboken, N.J., : John Wiley, c2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
New developments in medicinal chemistry [[electronic resource] /] / Marta P. Ortega and Irene C. Gil, editors |
Pubbl/distr/stampa | New York, : Nova Science Publishers, c2009 |
Descrizione fisica | 1 online resource (290 p.) |
Disciplina | 615/.19 |
Altri autori (Persone) |
OrtegaMarta P
GilIrene C |
Soggetto topico | Pharmaceutical chemistry |
Soggetto genere / forma | Electronic books. |
ISBN | 1-61728-546-3 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Folate biosynthesis : reappraisal of old and novel targets in the search for new antimicrobials / James Swarbrick ... [et al.] -- Studies on anti-cancer agents : phenolic compounds and their pharmacological activity / Maria Dolors Pujol and Isabel Sánchez -- Cytotoxic anticancer drugs from medicinal plants / Anh-Tho Nguyen and Pierre Duez -- Emerging applications of quantum dots in medicinal chemistry and drug development / Ian D. Tomlinson, Michael R. Warnement and Sandra J. Rosenthal -- Medicinal chemistry of copper and vanadium bioactive compounds / Susana B. Etcheverry and Patricia A.M. Williams -- Antimalarial peroxides : from artemisinin to synthetic peroxides / Jernej Iskra -- Chemical ecology and medicinal chemistry of marine NF-kB inhibitors / F. Folmer ... [et al.] -- Layered double hydroxides and their intercalation compounds in photo-chemistry and in medicinal chemistry / Umberto Costantino and Morena Nocchetti. |
Record Nr. | UNINA-9910460051403321 |
New York, : Nova Science Publishers, c2009 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|